- $141.30m
- $134.93m
- $7.14m
- 46
- 32
- 93
- 58
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 30.81 | ||
| Price to Tang. Book | 30.81 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 17.32 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -115.1% | ||
| Return on Equity | -5.5% | ||
| Operating Margin | -64.7% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 7.14 | 8.63 | 5.13 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. It is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its neflamapimod is in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies and early Alzheimer’s disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke. Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in dementia with Lewy bodies (DLB) and certain other neurological disorders. It is being evaluated in its ongoing RewinD-LB Trial, a Phase 2b study in patients with DLB.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- June 17th, 2015
- Public Since
- November 9th, 2016
- No. of Shareholders
- 115
- No. of Employees
- 8
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 8,253,741
- Address
- 20 Park Plaza, Suite 424, BOSTON, 02116
- Web
- https://cervomed.com/
- Phone
- +1 6177444400
- Contact
- Pj Kelleher
- Auditors
- KPMG LLP
Upcoming Events for CRVO
Q3 2024 CervoMed Inc Earnings Release
Similar to CRVO
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the CervoMed share price?
As of Today at 19:54 UTC, shares in CervoMed are trading at $19.92. This share price information is delayed by 15 minutes.
How has the CervoMed share price performed this year?
Shares in CervoMed last closed at $19.92 and the price had moved by +274.08% over the past 365 days. In terms of relative price strength the CervoMed share price has outperformed the S&P500 Index by +197.67% over the past year.
What are the analyst and broker recommendations for CervoMed?
The overall consensus recommendation for CervoMed is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the CervoMed dividend yield?
CervoMed does not currently pay a dividend.
Does CervoMed pay a dividend?
CervoMed does not currently pay a dividend.
When does CervoMed next pay dividends?
CervoMed does not currently pay a dividend.
How do I buy CervoMed shares?
To buy shares in CervoMed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of CervoMed?
As of the previous close price of $19.92, shares in CervoMed had a market capitalisation of $164.41m.
Where are CervoMed shares listed?
Here are the trading details for CervoMed:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CRVO
What kind of share is CervoMed?
Based on an overall assessment of its quality, value and momentum CervoMed is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a CervoMed share price forecast for 2024?
The analyst consensus target price for shares in CervoMed is $55.00. That is 176.1% above the last closing price of $19.92.
Analysts covering CervoMed currently have a consensus Earnings Per Share (EPS) forecast of -$1.67 for the next financial year.
What is the trend in the CervoMed share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CervoMed. Over the past six months, its share price has outperformed the S&P500 Index by +158.05%.
As of the last closing price of $19.92, shares in CervoMed were trading +45.85% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the CervoMed PE Ratio?
The CervoMed PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $19.92.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of CervoMed?
We do not have data on CervoMed's directors